TrialJournal of clinical pharmacology2022

Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors.

Xiaofei Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.